(Q36033310)

11 August 2017

1 reference

title

Tolcapone: a review of its use in the management of Parkinson's disease (English)

1 reference

Katherine A Lyseng-Williamson

11 August 2017

1 reference

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

11 August 2017

1

Gillian M Keating

1 reference

PubMed ID

15697329

11 August 2017

language of work or name

1 reference

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

19

1 reference

11 August 2017

2

1 reference

11 August 2017

165-184

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200519020-00006

11 August 2017

0 references

cites work

Medical and surgical treatment of Parkinson's disease. Strategies to slow symptom progression and improve quality of life

1 reference

12 December 2020

Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.

1 reference

12 December 2020

Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers

1 reference

12 December 2020

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

1 reference

12 December 2020

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

1 reference

12 December 2020

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.

1 reference

12 December 2020

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

1 reference

12 December 2020

Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease

1 reference

12 December 2020

Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease

1 reference

12 December 2020

Tolcapone: a novel approach to Parkinson's disease.

1 reference

12 December 2020

Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

1 reference

12 December 2020

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

1 reference

12 December 2020

Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease

1 reference

12 December 2020

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

1 reference

12 December 2020

Effects of entacapone and tolcapone on mitochondrial membrane potential

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease

1 reference

12 December 2020

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

1 reference

12 December 2020

Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease

1 reference

12 December 2020

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

1 reference

12 December 2020

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).

1 reference

12 December 2020

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD.

1 reference

12 December 2020

Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

1 reference

12 December 2020

Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease

1 reference

12 December 2020

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats

1 reference

12 December 2020

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

1 reference

12 December 2020

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.

1 reference

12 December 2020

Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.

1 reference

12 December 2020

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

1 reference

12 December 2020

Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa

1 reference

12 December 2020

Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline

1 reference

12 December 2020

Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group

1 reference

12 December 2020

Heart rate variability in Parkinson's disease patients treated with tolcapone

1 reference

12 December 2020

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

12 December 2020

Cognitive improvement during Tolcapone treatment in Parkinson's disease.

1 reference

12 December 2020

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

12 December 2020

Comparative tolerability of the newer generation antiparkinsonian agents

1 reference

12 December 2020

Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone

1 reference

12 December 2020

Entacapone-induced hepatotoxicity and hepatic dysfunction

1 reference

12 December 2020

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

1 reference

12 December 2020

Effect of tolcapone on the haemodynamic effects and tolerability of desipramine

1 reference

12 December 2020

Lack of interaction between tolcapone and tolbutamide in healthy volunteers

1 reference

12 December 2020

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

1 reference

12 December 2020

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

1 reference

12 December 2020

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

1 reference

12 December 2020

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

1 reference

12 December 2020

COMT inhibitors and liver toxicity.

1 reference

12 December 2020

Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II)

1 reference

12 December 2020

Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects

1 reference

12 December 2020

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

1 reference

12 December 2020

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

1 reference

12 December 2020

Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase

1 reference

12 December 2020

Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells

1 reference

12 December 2020

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

12 December 2020

Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.

1 reference

12 December 2020

10.2165/00023210-200519020-00006

Identifiers

DOI

1 reference

PubMed ID

15697329

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15697329